HOME >> MEDICINE >> NEWS
Preliminary US study findings support excellent results with CYPHER Sirolimus-eluting Stent

PARIS (May 22, 2002) -- Clinical investigators today reported preliminary findings at The Paris Course on Revascularization (PCR) documenting the excellent results of the CYPHER Sirolimus-eluting Stent in the first 400 patients enrolled in the landmark SIRIUS study. SIRIUS is a large-scale, randomized, double-blind, controlled clinical trial involving 53 U.S. treatment centers and 1,101 patients. The study was sponsored by Cordis Corporation, a Johnson & Johnson company.

Co-Principal Investigators, Martin B. Leon, M.D., and Jeffrey W. Moses, M.D., Interventional Cardiology, Cardiovascular Research Foundation, Lenox Hill Hospital, New York, NY, presented 8-month angiographic and 9-month clinical data. Peter J. Fitzgerald, M.D., Ph.D., Associate Professor of Medicine and Director of the CV Core Analysis Laboratory, Stanford University Medical Center, Palo Alto, CA, presented 8-month intravenous ultrasound (IVUS) data on 96 patients.

The SIRIUS preliminary data are the most recent in a series of study findings evaluating the efficacy and safety of the CYPHER Sirolimus-eluting Stent in reducing reblockage of de novo coronary artery lesions.

"We are extremely impressed by the consistency in findings between the preliminary SIRIUS data and the results of the large-scale RAVEL* study in Europe and Latin America," said Dr. Leon.

Eight-month angiographic follow-up showed virtually no in-stent late lumen loss (0.14 mm) in patients treated with the CYPHER Stent, mirroring the 6-month findings of the RAVEL study and the 2-year findings of the First-in-Man study. The 2% rate of angiographic in-stent restenosis representing a 94% reduction versus the control arm (bare metal stent) supports the findings of earlier studies.

"The major reductions in angiographic in-stent restenosis and late lumen loss associated with the CYPHER Sirolimus-eluting Stent are proving to be remarkably similar from study to study," said Dr. Leon. "S
'"/>

Contact: Martin E. Schildhouse
mschildh@crdus.jnj.com
305-606-3577
Cordis Corporation
22-May-2002


Page: 1 2 3

Related medicine news :

1. Preliminary results are promising in Alzheimers gene therapy trial
2. Preliminary report suggests combination therapy may help treat SARS
3. Preliminary study finds stem cells in blood restore damaged heart muscle
4. Preliminary study suggests endomitriosis could contribute to infertility
5. Preliminary study shows high-dose coenzyme Q10 slows functional decline in Parkinsons patients
6. Preliminary Study Proves Centuries Of Herbalists Right About Echinacea
7. ACTG 315 Preliminary Results: Drug Cocktail Restores Partial Immune Function
8. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
9. UMaine study looks at infants and chronic nighttime crying
10. Chronic pain treatments more effective when taken together, new study shows
11. UNC study: Most N.C. family practitioners engage in unrecognized community service

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/31/2020)... Hawaii (PRWEB) , ... August 31, 2020 , ... A Cure for Covid-19 “PTS” with ... people on the planet are in a state of panic, experiencing deep anxiety, immense stress, ... Right now, a solution is timely when most people on the planet are experiencing a ...
(Date:8/31/2020)... ... August 31, 2020 , ... Bonde ... for patients with advanced heart failure, today announced that the company has been ... of $555,358 from the National Heart, Lung, and Blood Institute of the National ...
(Date:8/28/2020)... ... August 28, 2020 , ... WHAT , Hespiro™ ... patients with respiratory conditions, including COVID-19, while reducing the need for scarce mechanical ... captures exhaled gas and scrubs it free of carbon dioxide in a completely ...
(Date:8/28/2020)... ... ... Integrated Viral Protection (IVP Air) today announced that the True ... Mobile Biodefense Indoor Air Protection System that is the first system designed and proven ... equipped with the filtration system on September 8th. , The IVP Air S1 ...
(Date:8/27/2020)... GREENVALE, N.Y. (PRWEB) , ... August 27, 2020 ... ... Loren DePinto, has joined the Walk-in Dermatology team in its Greenvale, New York ... Long Island Nail and Skin Care Institute. She is certified in chemical peels, ...
Breaking Medicine News(10 mins):
(Date:8/26/2020)... CHARLES, Mo. (PRWEB) , ... ... ... Services, a member of Eurofins BioPharma Services, Laboratory Testing division, expands its ... the existing suite of Flow Cytometry platforms available. With industry-leading biomarker solutions, ...
(Date:8/26/2020)... , ... August 26, 2020 , ... As the U.S. ... the daily routine for preventing the Coronavirus. Wear a mask, keep your distance, wash ... advocate Dr. Denis Burkitt said it best in 1977, “How much better it is ...
(Date:8/26/2020)... (PRWEB) , ... August 26, 2020 , ... ... largest non-profit organization devoted to funding innovative lymphoma research and serving the lymphoma ... 25th Anniversary with a special virtual LRF Gala and Charity Auction on ...
Breaking Medicine Technology:
Cached News: